Diagnostic Criteria & Workup for MS

2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis is a revision to the 2018 CMSC protocol and guidelines. The recommendations were published to better inform MRI in MS clinical practice and include the following updates:

Translational research in MRI
Modifications to MRI acquisition to increase diagnostic accuracy, improve new lesion identification and monitor treatment
Additional guidance on the safe use of gadolinium-based contrast agents (GBCAs)
MRI use in certain populations (pediatric MS, during pregnancy and postpartum)
A focus on standardized MRI protocols and reporting

" c-nmssatomrichtext_nmssatomrichtext-host="">

The new 2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis is a revision to the 2018 CMSC protocol and guidelines. The recommendations were published to better inform MRI in MS clinical practice and include the following updates:

Translational research in MRI
Modifications to MRI acquisition to increase diagnostic accuracy, improve new lesion identification and monitor treatment
Additional guidance on the safe use of gadolinium-based contrast agents (GBCAs)
MRI use in certain populations (pediatric MS, during pregnancy and postpartum)
A focus on standardized MRI protocols and reporting

Translational research in MRI
Modifications to MRI acquisition to increase diagnostic accuracy, improve new lesion identification and monitor treatment
Additional guidance on the safe use of gadolinium-based contrast agents (GBCAs)
MRI use in certain populations (pediatric MS, during pregnancy and postpartum)
A focus on standardized MRI protocols and reporting

" c-nmssatomrichtext_nmssatomrichtext-host="">

Translational research in MRI
Modifications to MRI acquisition to increase diagnostic accuracy, improve new lesion identification and monitor treatment
Additional guidance on the safe use of gadolinium-based contrast agents (GBCAs)
MRI use in certain populations (pediatric MS, during pregnancy and postpartum)
A focus on standardized MRI protocols and reporting

Gadolinium FDA Drug Safety Communication

View the Criteria

Diagnostic Workup

Gadolinium FDA Drug Safety Communication

Diagnostic Workup Tools